AUTHOR INFORMATION

We consider unsolicited manuscripts for publication in Future Medicine journals, including positive, negative or inconclusive data. Articles published in the journals are subject to rigorous double-blind peer review by independent experts in the field. Details of the article types considered are contained within the Author Guidelines. If you are interested in submitting an article, please contact us with a brief proposal and article outline in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Advisory Board, solicits articles for publication.

• Author Guidelines
• Future Medicine Author Guidelines
• Future Medicine Management Series Author Guidelines
• Drug, Device & Vaccine Evaluation Author Guidelines
  
• Clinical Trial Protocol & Clinical Trial Evaluation Author Guidelines
• Methods Reporting Checklist for Authors
• Author Forms
  
• Author Disclosure Forms
• Copyright Assignment Form
• Open Access Forms
• Accelerated Publication Form
  
• References
• Reference Manager style
• EndNote style
• Permissions for reproduced or adapted material within your article
  
• Pre-submission editing services
  
• Submission
• Accelerated publication option
• Editorial Policies
• Manuscript submission & processing
• External peer review
• Revision
• Post-acceptance
• Embargo policy
  
• Disclosure & conflict of interest policy
• Ethical conduct of research
• Patients’ rights to privacy
• Use of personal communications & unpublished data
• Clinical trial registration
• Errata/corrigenda
• Duplicate publication/submission & plagiarism
• Scientific misconduct & retraction
• Compliance with funder open or public access policies
• Manuscript deposition service for authors (NIH- and Wellcome Trust-funded articles)
• Self-archive policy
• Author options post-publication
• Open access option
• Access tokens
• Kudos
• Altmetric
  

Author Guidelines

These documents outline how to prepare articles for submission to Future Medicine journals. We recommend you read these guidelines in full before submitting your article or making an article proposal. These documents also include full details of our journal policies (which are also given on this page).

Future Medicine Author Guidelines

Download here.

Future Medicine Management Series Author Guidelines

Download here.

Drug, Device & Vaccine Evaluation Author Guidelines

Separate author guidelines for the submission of these article types are available. Please contact Henry Ireland, Drug Evaluations Commissioning Editor, to request a copy.

Clinical Trial Protocol & Clinical Trial Evaluation Author Guidelines

Separate author guidelines for the submission of these article types are available. Please contact Henry Ireland, Drug Evaluations Commissioning Editor, to request a copy.

Methods Reporting Checklist for Authors

To assist our authors in maintaining good reporting standards, we have compiled a Methods Reporting Checklist for Authors, which is available here. Authors submitting any type of original research, health economic evaluations, observational studies, systematic reviews and meta-analyses should consult the relevant checklist when completing their article, and submit it alongside their manuscript wherever possible.

back to top

Author Forms

These documents should be completed and submitted alongside article submissions as appropriate.

Author Disclosure Forms

For the following article types, please use the disclosure form available here.

• Drug Evaluations
• Device Evaluations
• Vaccine Evaluations
• Clinical Trial Protocols
• Clinical Trial Evaluations
  

For all other article types, please use the following disclosure forms:

• Biomarkersin Medicine
  

• Breast Cancer Management
  
• CNS Oncology
  
• Colorectal Cancer
  
• Concussion
  
• Epigenomics
  
• Future Cardiology
  
• Future Microbiology
  
• Future Neurology
  
• Future Oncology
  
• Future Virology
  
• Hepatic Oncology
  
• Immunotherapy
  
• International Journal of Endocrine Oncology
  
• International Journal of Hematologic Oncology
  
• Journal of 3D Printing in Medicine
  
• Journal of Comparative Effectiveness Research
  
• Lung Cancer Management
  
• Melanoma Management
  
• Nanomedicine
  
• Neurodegenerative Disease Management
  
• Pain Management
  
• Personalized Medicine
  
• Pharmacogenomics
  
• Regenerative Medicine
  
• Women's Health
  

Copyright Assignment Form

For articles where copyright is to be assigned to the journal, please complete the Copyright Assignment Form available here.

Open Access Forms

For articles where the author has opted to publish Open Access, authors are required to complete a license form and payment form. For more information on the Open Access option, please see below.

Accelerated Publication Form

back to top

References

Reference Manager style

1. Download the Future Medicine Reference Manager Style here.
2. Once the file is downloaded to your desktop, copy the file to the appropriate folder in your program directory (usually located in C:\Program Files\ReferenceManager\Styles).

EndNote style

Follow the instructions that are appropriate for your version of EndNote as listed below:

Installing the style into EndNote X2 and later:

1. Download the Future Medicine EndNote style for references here (compatible with Mac EndNote 9).
2. In Windows, or using your Macintosh Finder, browse to the location where you downloaded the style. Double-click on the style file to open it. It should open in the EndNote program.
3. In EndNote, go to the "File Menu" and choose "Save as”.
4. Remove the word "copy" from the end of your style's name, and then click the "Save" button.
5. Click on the "File Menu" and choose "Close Style”.

Installing the style into EndNote 8, 9, X, or X1:

1. Download the Future Medicine EndNote style for references here (compatible with Mac EndNote 9).
2. Using Windows, or using your Macintosh Finder, browse to the location where you downloaded the style. Right-click on the style file and select “Copy”.
3. Browse to your Endnote Styles folder. This will typically be in following location: Windows: C:\Program Files\EndNote #\Styles (where # is the version number for EndNote); Mac OS: Applications\EndNote #\Styles (where # is the version number for EndNote); Note: If you modify the EndNote preferences, you can set this to another location. To check this setting, go to the "Edit" menu or EndNote menu on the Mac and select "Preferences”. Click on the Folder Locations option to see the custom Style folder location and modify as needed. Keep in mind that the default location for the Styles folder may cause problems when trying to save or edit in Windows Vista and 7 with versions prior to EndNote X2.
4. Right-click in this folder and choose “Paste”. Your style should now be installed in the EndNote program.

If you require further assistance or have any questions, please contact us.

back to top

Permissions for reproduced or adapted material within your article

As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be time-consuming, it is wise to request permission as soon as possible. Please send us copies of emails, letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Keep the originals for your files. If payment is required for use of the figure, this should be covered by the author.

Future Medicine is a signatory to the STM Permissions Guidelines produced by the International Association of Scientific, Technical and Medical Publishers (http://www.stm-assoc.org/). Permission is, or in the case of an express permission requirement should be, granted free of charge by signatory organizations, with respect to a particular journal article or book being prepared for publication, to:

• Use up to three figures (including tables) from a journal article or book chapter, but:
• not more than five figures from a whole book or journal issue/edition;
• not more than six figures from an annual journal volume; and
• not more than three figures from works published by a single publisher for an article, and not more than three figures from works published by a single publisher for a book chapter (and in total not more than thirty figures from a single publisher for re-publication in a book, including a multi-volume book with different authors per chapter).
• Use single text extracts of less than 400 words from a journal article or book chapter, but not more than a total of 800 words from a whole book or journal issue/edition.

Permission to go beyond such limits may be sought although in such instances the permission grant may require permission fees. Important – although permission may be granted without charge, authors must ensure that appropriate permission has nevertheless been obtained. Co-signatories of the permissions agreement can be found on the following website: http://www.stm-assoc.org/copyright-legal-affairs/permissions/permissions-guidelines/.

back to top

Pre-submission editing services

Future Medicine partners with Enago to provide pre-submission editing services for our authors. Editing services include:

• Language check
• Copyediting
• Substantive editing
  

For more information, please visit the website here: http://futuremedicine.enago.com

back to top

Submission

Where possible, authors should submit their article via our online submission system. If you have any difficulties submitting, please contact our editorial team by email (see Contact Us). You can access our online submission system here, where guides to using the submission system can also be found. Submitting authors will receive confirmation of receipt and will be able to discuss the status of their article, by telephone or e-mail (where possible, please refer to your manuscript ID number in any communications). Article status can also be viewed via the Author Center in the online submission system. We aim to respond to any query (editorial or otherwise) within 1 working day.

Authors are also welcome to contact the editorial team with article outlines, to discuss their suitability for submission.

Please submit manuscripts in Microsoft Word format. All figures, tables and boxes should be submitted in an editable format. Ideally these should be sent as Microsoft Word, Microsoft Excel or Adobe Illustrator files.

If you are uncertain who to contact or have any queries about your contribution, please contact Laura Dormer, Editorial Director.

back to top

Accelerated publication option

Our fee-based accelerated publication option provides publication of accepted articles online ahead of the print issues, within 6 weeks of submission (subject to receiving a signed Accelerated Publication Agreement form on the day of submission, and acceptance following peer review and article revisions). If you are interested in this option, please complete the Accelerated Publication Agreement form, and submit this along with your first draft.

Accelerated publication fees are as follows:

Discounts are available for authors who have also opted to publish open access.

back to top

Editorial Policies

Future Medicine’s Editorial Policies are contained within the Author Guidelines documents above, and also included in full below:

Future Medicine titles endorse the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, issued by the International Committee for Medical Journal Editors, the Code of Conduct and Best Practice Guidelines for Journal Editors, produced by the Committee on Publication Ethics, and GPP3 (http://www.ismpp.org/gpp3).

Manuscript submission & processing

Future Medicine titles publish a range of article types, including solicited and unsolicited reviews, perspectives and original research articles. Receipt of all manuscripts will be acknowledged within 1 week and authors will be notified as to whether the article is to progress to external review. Initial screening of articles by internal editorial staff will assess the topicality and importance of the subject, the clarity of presentation, and relevance to the audience of the journal in question.

If you are interested in submitting an article, or have any queries regarding article submission, please contact the Commissioning Editor for the journal, via Laura Dormer, Editorial Director. For new article proposals, the Commissioning Editor will require a brief article outline and working title in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Board, solicits articles directly for publication.

External peer review

Through a rigorous peer-review process, Future Medicine titles aim to ensure that articles are unbiased, scientifically accurate and clinically relevant. Articles are peer reviewed by three or more members of the International Editorial Board or other specialists selected on the basis of experience and expertise. Review is performed on a double-blind basis – the identities of peer reviewers and authors are kept confidential. Peer reviewers must disclose potential conflicts of interests that may affect their ability to provide an unbiased appraisal (see Conflict of Interest Policy below). Peer reviewers complete a referee report form, to provide general comments to the editor and both general and specific comments to the author(s).

Where an author believes that an editor has made an error in declining a paper, they may submit an appeal. The appeal letter should clearly state the reasons why the author(s) considers the decision to be incorrect and provide detailed, specific responses to any comments relating to the rejection of the article. Further advice from members of the journal’s Editorial Board and/or other external experts will be sought regarding eligibility for re-review.

Revision

Most manuscripts require some degree of revision prior to acceptance. Authors should provide two copies of the revised manuscript – one of which should be highlighted to show where changes have been made. Detailed responses to reviewers’ comments are also required (authors should complete these sections in the supplied Peer Review Report Form). Manuscripts may be accepted at this point or may be subject to further peer review. The final decision on acceptability for publication lies with the journal editor.

Post-acceptance

Accepted manuscripts will undergo production in-house. This will involve type-setting, copy-editing, proof-reading and re-drawing of any graphics. Authors will receive proofs of their article for approval and sign off and will be asked to sign a transfer of copyright agreement, except in circumstances where the author is ineligible to do so (e.g., government employees in some countries)

Please note that once the author receives the copy of their article for approval, our production department will need to hear from them within a tight deadline to ensure the issue is published on schedule. If you believe you may be away and unable to check the galley proofs at any point, please let the Commissioning Editor know.

Embargo policy

• Following the acceptance of articles for publication, authors (and their institutions, etc.) are welcome to publicize the publication; authors wishing to do so, should advise the editor of the details beforehand.

• No publicity relating to publication in a Future Medicine journal should be carried out while the manuscript is under consideration. However, prior publicity linked to presentations at meetings does not jeopardize publication in a Future Medicine journal.

• In cases where data may be of overwhelming public health importance, the above policy may be waived; should this be the case, the appropriate authorities responsible for public health should decide whether to disseminate information to physicians and the media in advance and should be responsible for this decision. The journal editor should be informed if these circumstances apply.

Any queries relating to publicity of manuscripts should be directed to the journal editor.

Disclosure & conflict of interest policy

Authors must state explicitly whether financial and/or nonfinancial relationships exist that potentially conflict with the subject matter or materials discussed in the manuscript and any such potential conflict of interest (including sources of funding) should be summarized in a separate section of the published article. Authors must disclose whether they have received writing assistance and identify the sources of funding for such assistance. Authors declaring no conflict of interest are required to publish a statement to that effect within the article.

Authors must certify that they have disclosed relationships in which they (or a close family member): is employed, is a contractor, provides services, or has otherwise collaborated in commercial or scientific pursuits – even in the absence of direct monetary remuneration. Stock holdings and issued or pending patents of an author or family member should also be disclosed. This is list is not exclusive of other forms of financial involvement. A 36-month disclosure window should be used. Details of relevant conflicts of interests (or the lack of) must be declared in the ‘Disclosure’ section of the manuscript for all listed authors.

External peer reviewers must disclose any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. Should any such conflict of interest be declared, the journal editor will judge whether the reviewer’s comments should be recognized or will interpret the reviewer’s comments in the context of any such declaration.

Ethical conduct of research

For studies involving data relating to human or animal experimental investigations, appropriate institutional review board approval is required and should be described within the article. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations involving human subjects, authors should explain how informed consent was obtained from the participants involved.

Patients’ rights to privacy

Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be included unless the information is essential for scientific purposes and the patient (or parent or legal guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. When informed consent has been obtained it should be indicated in the manuscript.

In attempting to maintain patient anonymity, identifying details should be omitted where they are not essential. However, patient data should never be amended or falsified. Informed consent should be obtained whenever there is any doubt that anonymity can be assured.

Use of personal communications & unpublished data

Where an individual is identified within an article as a source of information in a personal communication or as a source for unpublished data, authors should include a signed statement of permission from the individual(s) concerned and specify the date of communication.

Clinical trial registration

Future Medicine titles prefer to publish clinical trials that have been included in a clinical trials registry that is accessible to the public at no charge, is electronically searchable, is open to prospective registrants and is managed by a not-for-profit organization, such as www.clinicaltrials.gov (sponsored by the United States National Library of Medicine). Where a clinical trial registration number is available, this should be included at the end of the abstract and also listed the first time the authors use a trial acronym to refer to the trial they are reporting in the manuscript. Unregistered clinical trials should be declared as such, and the reason for nonregistration should be provided.

Whilst referees will take registration status into account, all well-designed and presented trials and corresponding data will be considered for publication.

Errata/corrigenda

Mistakes by either editor or author should be identified wherever possible and an erratum or corrigendum published at the earliest opportunity. We will attempt to contact the author of the original article to confirm any error, and publish an appropriate erratum or corrigendum at the earliest opportunity.

Duplicate publication/submission & plagiarism

All manuscripts submitted to Future Medicine titles are considered for publication on the understanding that they have not been published previously elsewhere or are under consideration for publication elsewhere. The journal may, however, consider republication of a paper previously published in a language other than English, subject to prominent disclosure of the original source and with any necessary permission. Authors will be asked to certify that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere.

Where specific findings from a particular study have been previously published (in Future Medicine titles or elsewhere), Future Medicine titles will not consider manuscripts reporting the same findings, except where:

• the results are substantially reanalyzed, reinterpreted for a different audience, or translated into another language;

• the primary publication is clearly acknowledged and cited and the trial registration number(where available) of the original research is included; and

• the publication is clearly presented as an analysis derived from the primary publication results or marked as a translation, with appropriate permission obtained from the previous publisher and copyright laws upheld.

All submitted articles will be evaluated using plagiarism detection software, which compares the submitted manuscript with full text articles from all major journal databases and the internet.

The use of published or unpublished ideas, words or other intellectual property derived from other sources without attribution or permission, and representation of such as those of the author(s) is regarded as scientific misconduct and will be addressed as such.

Scientific misconduct & retraction

If misconduct by authors or reviewers is suspected, either pre- or post-publication, action will be taken. An explanation will be sought from the party or parties considered to be involved. If the response is unsatisfactory, then an appropriate authority will be asked to investigate fully. Future Medicine will make all reasonable attempts to obtain a resolution in any such eventuality and correct the record or archive as necessary (publishing a retraction of the article as required).

Compliance with funder open or public access policies

Future Medicine is supportive of open and public access policies mandated by various funding bodies (see list below). In the first instance, please check whether your article type is covered by your funder mandate (i.e., in some cases, funder policies only cover research articles, rather than review articles). Please advise the Editor on submission if your article was funded by any of the bodies below.

Where open access publication is a requirement of your funding, our article processing charge will need to be paid (in many cases, this will be covered by your funder, and you should check the specific details of this on the funder website). Please see further information below on our Open Access Option for authors.

As standard for our Open Access option, articles are published under a CC BY-NC-ND license, and this will be used in the first instance; however, where the funder requires it, articles can be published under a difference Creative Commons license (i.e., the CC BY license in the case of The Wellcome Trust).

Funding bodies:

• Action on Hearing
• Alzheimer’s Society
• Arthritis Research UK
• Austrian Science Fund (FWF)
• Biotechnology and Biological Sciences Research Council (BBSRC)
• Bloodwise
• Breast Cancer Now
• British Heart Foundation (BHF)
• Cancer Research UK (CRUK)
• Chief Scientist Office
• Diabetes UK
• Dunhill Medical Trust
• European Research Council (ERC)
• Marie Curie Cancer Care
• Medical Research Council (MRC)
• Motor Neuron Disease Association
• Multiple Sclerosis Society
• Myrovlytis Trust
• National Centre for the Replacement, Refinement and Reduction of Animals in Research
• National Institute for Health Research (Department of Health)
• Parkinson's UK
• Prostate Cancer UK
• Telethon Italy
• The Wellcome Trust
• World Health Organization
• Worldwide Cancer Research
• Yorkshire Cancer Research

NB. The above list of funders may not be exhaustive; should you have requirements related to a funder that is not listed above, please contact Laura Dormer, Editorial Director, to discuss further.

Manuscript deposition service for authors (NIH- and Wellcome Trust-funded articles)

To assist our NIH- and Wellcome Trust-supported authors in meeting the requirement to deposit their article with PubMed Central (NIH) and Europe PMC (Wellcome Trust), Future Medicine will deposit the final published PDF of the article on their behalf, within 2 weeks of online publication. Authors will then be contacted to provide the final information to complete the process (i.e., funding source).

In the case of NIH-funded authors, articles will be freely accessible via PubMed Central and searchable within its index no later than 12 months after publication. Wellcome Trust-funded articles will be deposited with Europe PMC and made open access under a Creative Commons CC BY license upon publication (subject to receipt of the article processing charge). Wellcome Trust-funded authors are required to complete the Open Access license form and payment form found below.

If you require further assistance or have any questions, please contact Laura Dormer, Editorial Director, to discuss further.

Self-archive policy

Future Medicine is supportive of self-archiving. Should you be interested in archiving your work, please be aware of the policies below.

Definition of article versions:

• Submitted version – authors’ version of the article that has been submitted to the journal and entered into the peer-review process (no revisions have yet been made).
• Authors’ final version – authors’ version of the article that has been through the peer-review process, revised accordingly, and accepted for publication by the journal.
• Version of record – Future Medicine’s version of the article that has been accepted for publication and typeset into the final journal format (including copyediting, formatting, re-drawing of illustrations, etc.).

The Future Medicine self-archiving policies differ depending on the final copyright status of your article. Authors should adopt the self-archiving policy corresponding to the publishing route that they have opted for. The first section sets out the policy applicable for instances where copyright is assigned to the publisher. The subsequent section explains the rights applicable where an author has chosen the open access option.

Where copyright is assigned to the publisher (standard publication option requiring no article processing charge):

The rights outlined here apply in circumstances where copyright has been assigned to the publisher. If your institution/funder requires you to follow rules other than the below, please inform the Editor.

a) Submitted version

• Share print or electronic copies of the article with colleagues. In doing so, they should state that the article has been submitted for publication to [the specified journal].
• Post an electronic version of an article on a personal website, the website of an employer or institution, or to free public servers. 

b) Authors’ final version

• Share print or electronic copies of the article with colleagues.
• 3 months after publication – post the Authors’ final version on a personal website.
• Subject to appropriate acknowledgment of the journal and full bibliographic reference to the article.
• 12 months after publication – post the Authors’ final version on their employer’s website or on free public servers in their subject area.
• Subject to appropriate acknowledgment of the journal and full bibliographic reference to the article.

c) Version of record

Should the author wish to do any of the above within a shorter timeframe than specified, requests should be directed to Future Medicine via our Permissions Requests page. 

Please see our Permissions Requests page for information on the rights authors retain to re-use parts of their article in future works (including in a thesis/dissertation). Authors cannot reproduce an article for commercial purposes (i.e., for monetary gain on their own account or on that of a third party, or for indirect financial gain by a commercial entity). However, this does not affect an author’s rights to receive a royalty or other payment for works of scholarship.

Articles published via the open access option (article processing fee applies):

The rights outlined below apply specifically to all articles published via the open access option route.

Using the standard Future Medicine open access option, articles are published under a Creative Commons CC BY-NC-ND license, which allows dissemination on an open access basis, but does not permit commercial exploitation or the creation of derivative works without permission (for further details from www.creativecommons.org). Please see our Permissions Requests page to request permissions in these circumstances.

Provided that authors give appropriate acknowledgment to the journal and publisher, and cite the full bibliographic reference for the article, when it is published open access (i.e., when the article processing fee has been received), authors may:

• Share print or electronic copies of an article with colleagues
• Post the version of record on:
• Personal websites
• An employer’s website
• Free public servers in their subject area
• Use all or part an article and abstract in personal compilations or other scholarly publications of their own work (and may receive a royalty or other payment for such work)
• Use an article within their employer’s institution or company for educational or research purposes, including use in course packs

Electronic versions of an accepted article should include a link to the published version of the article together with the following: ‘For full bibliographic citation, please refer to the version available at www.futuremedicine.com’.

Third parties are entitled to use an article published via the open access option route, in whole or in part, in accordance with the conditions outlined in the CC BY-NC-ND license (see information above).

back to top

Author options post-publication

Open access option

For authors interested in the journal Concussion (a fully open access journal), please click here for open access information relevant to that journal.

Authors who wish to publish in any Future Medicine title can opt for our Open Access Option, allowing unrestricted access to the online version of their article. The Open Access Option is available for all article types except Drug, Device and Vaccine Evaluation articles.

Authors of accepted articles may choose to pay a fee in order for their published article to be made accessible on an open access basis at www.futuremedicine.com and flagged as such on the website. Using this option, articles are published under a Creative Commons CC BY-NC-ND license, which allows dissemination on an open access basis, but does not permit commercial exploitation or the creation of derivative works without permission (for further details from www.creativecommons.org). Please see our Permissions Requests page to request permissions in these circumstances.

Open Access Option fees are as follows:

Authors are required to complete a license form and payment form. The publication fee is charged on acceptance of the article and payment in full should be paid within 30 days (preferably by credit card) by the author or other funding body. Authors not paying by credit card may request to be invoiced in US Dollars or Euros at the prevailing equivalent rate (using www.xe.com). The source of funding for open access fees should be included in the Financial & Competing Interests Disclosure statement.

Please note that, for authors taking this option, the open access fee must be paid before the article is published online. This is to ensure we can maximize the readership of your article from day one of publication.

Authors based in countries (or who have received their funding from countries) classed by the World Bank as lower or lower-middle income (http://data.worldbank.org/about/country-and-lending-groups) are eligible to apply for a 50% discount on article processing charges. Full waivers may also be granted in certain cases. Authors who believe they are eligible should request this when submitting their article to the relevant journal, and should provide the journal editor with details of their affiliation or funding source as appropriate (including whether the funding body has policies related to mandatory open access publication.

All articles are subject to our standard peer-review process and will be accepted or rejected based on their own merit.

Use by commercial 'for-profit' organizations:

Use of Open Access Option articles for commercial purposes is not permitted. However, support for free access is available to third parties subject to the appropriate permission fees (contact: reprints@futuremedicine.com).

Commercial purposes include:

• Copying or downloading of articles, or linking to such articles for further redistribution, sale or licensing
• Copying, downloading or posting by a site or service that incorporates advertising with such content
• The inclusion or incorporation of article content in other works or services (other than normal quotations with an appropriate citation) that is then available for sale or licensing, for a fee (for example, a compilation produced for marketing purposes, inclusion in a sales pack)
• Use of article content (other than normal quotations with appropriate citation) by for-profit organizations for promotional purposes
• Linking to article content in e-mails redistributed for promotional, marketing or educational purposes
• Use for the purposes of monetary reward by means of sale, resale, license, loan, transfer or other form of commercial exploitation such as marketing products
• The reproduction of the article in whole in paper format, e.g., reprints
  

Print reprints of Open Access Option articles can be purchased from reprints@futuremedicine.com.

If you have a query regarding our Open Access Option please contact Francesca Lake, Managing Editor – Open Access.

Access tokens

• What is an access token?
• An access token allows a single user to access a certain amount of content an indefinite number of times. Most commonly, this is a single article – but can be any set of content, up to and including access to all of our content. Please note that access tokens are only available to authors for non-commercial purposes. For authors or third parties wishing to host an article on a company website, please contact reprints@futuremedicine.com.
• Why use an access token?
• An access token offers a cost-effective and time-efficient way of offering access to a targeted group of people. It allows an author to share their work with their colleagues, peers and friends effortlessly by providing them a link to directly access the article, increasing the visibility of the article and its readership.
• How does it work?
• An author should request access tokens directly through a staff member of Future Medicine, stating the article which they wish to purchase the tokens for.
• Once payment has been processed, the access tokens are immediately available for activation. The author will receive an automated e-mail that contains the details of how to share the access tokens with their colleagues, peers and friends – including suggested text which they can use as the base for any e-mail they might send.
• Each user who wishes to access the content must be provided with the activation link (contained in the e-mail the author receives) – in order to access the content, they must simply click on the link, then register (or login, if already a registered user) and the content will be available to them.
• There is no time limit within which the tokens must be activated, so there is no pressure on the author to ensure the content is accessed immediately.
• Once all the access tokens have been used, additional bundles of 50 can be purchased and the author can continue to distribute their content in the same way as described above.
• Costs
• Access tokens can be purchased in bundles of 50 at a time at a cost of £105 per 50 tokens, which is very cost effective compared with a single user purchasing a single pay-per-view article. Therefore, an author can share their work at a cost of only £2.10 per person – with no expiry date.

back to top

Kudos

We are delighted to partner with Kudos to bring our authors online tools to increase the reach of their work. For more information on how this will enhance publishing your article with Future Medicine go to http://www.futuremedicine.com/page/kudos.

back to top

Altmetric

All Future Medicine articles are tracked by Altmetric, with each article receiving a score reflecting the quantity and reach of the attention it has received. Click on this score on each article page to find out more about how much and where an article is being talked about! For more information on Altmetric, go to https://www.altmetric.com.

back to top